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Articles
Emergence of dominant toxigenic M1T1 
Streptococcus pyogenes clone during increased scarlet fever 
activity in England: a population-based molecular 
epidemiological study
Nicola N Lynskey*, Elita Jauneikaite*, Ho Kwong Li, Xiangyun Zhi, Claire E Turner, Mia Mosavie, Max Pearson, Masanori Asai, Ludmila Lobkowicz, 
J Yimmy Chow, Julian Parkhill, Theresa Lamagni, Victoria J Chalker, Shiranee Sriskandan
Summary
Background Since 2014, England has seen increased scarlet fever activity unprecedented in modern times. 
In 2016, England’s scarlet fever seasonal rise coincided with an unexpected elevation in invasive Streptococcus pyogenes 
infections. We describe the molecular epidemiological investigation of these events.
Methods We analysed changes in S pyogenes emm genotypes, and notifications of scarlet fever and invasive disease in 
2014–16 using regional (northwest London) and national (England and Wales) data. Genomes of 135 non-invasive and 
552 invasive emm1 isolates from 2009–16 were analysed and compared with 2800 global emm1 sequences. Transcript 
and protein expression of streptococcal pyrogenic exotoxin A (SpeA; also known as scarlet fever or erythrogenic 
toxin A) in sequenced, non-invasive emm1 isolates was quantified by real-time PCR and western blot analyses.
Findings Coincident with national increases in scarlet fever and invasive disease notifications, emm1 S pyogenes upper 
respiratory tract isolates increased significantly in northwest London in the March to May period, from five (5%) of 
96 isolates in 2014, to 28 (19%) of 147 isolates in 2015 (p=0·0021 vs 2014 values), to 47 (33%) of 144 in 2016 (p=0·0080 vs 
2015 values). Similarly, invasive emm1 isolates collected nationally in the same period increased from 183 (31%) of 
587 in 2015 to 267 (42%) of 637 in 2016 (p<0·0001). Sequences of emm1 isolates from 2009–16 showed emergence of 
a new emm1 lineage (designated M1UK)—with overlap of pharyngitis, scarlet fever, and invasive M1UK strains—which could 
be genotypically distinguished from pandemic emm1 isolates (M1global) by 27 single-nucleotide polymorphisms. Median 
SpeA protein concentration in supernatant was nine-times higher among M1UK isolates (190·2 ng/mL 
[IQR 168·9–200·4]; n=10) than M1global isolates (20·9 ng/mL [0·0–27·3]; n=10; p<0·0001). M1UK expanded nationally to 
represent 252 (84%) of all 299 emm1 genomes in 2016. Phylogenetic analysis of published datasets identified single 
M1UK isolates in Denmark and the USA.
Interpretation A dominant new emm1 S pyogenes lineage characterised by increased SpeA production has emerged 
during increased S pyogenes activity in England. The expanded reservoir of M1UK and recognised invasive potential of 
emm1 S pyogenes provide plausible explanation for the increased incidence of invasive disease, and rationale for 
global surveillance.
Funding UK Medical Research Council, UK National Institute for Health Research, Wellcome Trust, Rosetrees Trust, 
Stoneygate Trust.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Scarlet fever is a classic exanthem of childhood caused 
by the bacterium Streptococcus pyogenes (group A strepto­
coccus) that, until the beginning of the 20th century, was 
associated with frequent loss of life among children.1 By 
the start of the 20th century, long before widespread use 
of antibiotics, the incidence and severity of scarlet fever 
had begun to fall, a phenomenon that remains largely 
unexplained.2 One potential (untestable) hypothesis is 
that the streptococcal bacteria causing the disease might 
have undergone a pathogenetic change that led to a 
reduction in the invasive and septic sequelae of scarlet 
fever.
Since the 1940s, scarlet fever has followed a seasonal 
springtime pattern—peaking between March and May 
while remaining less frequent throughout the rest of the 
year—without the major cyclical epidemics observed in 
the early 20th century.3 Surges in invasive infections can 
periodically follow a similar seasonal pattern for reasons 
that are incompletely understood. In 2014, England had 
an unexpected surge in scarlet fever infections, with over 
15 000 disease notifications—a marked increase in inci­
dence compared with previous decades.3,4 Despite 
having a major impact on public health resources,3 the 
increase in infections was not associated with any 
rise in the incidence of invasive disease. Even greater 
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seasonal upsurges of scarlet fever were observed in 
2015, when there were over 17 000 notifications, and in 
2016, when there were over 19 000 notifications.3 In the 
spring of 2016, there was a 1·5­times increase in the 
number of laboratory­confirmed invasive S pyogenes 
infections compared with that in the previous 5 years, 
coinciding with the peak in scarlet fever notifications.3,5 
The absence of any association between scarlet 
fever notifications and increased invasive infection 
notifications in 20143 led us to speculate that the 
association of scarlet fever with invasive disease in 
2016 might be strain dependent.
Microbiological surveillance of S pyogenes upper 
respiratory tract infections in England is constrained, as 
most doctors do not routinely take samples for 
bacteriological diagnosis of sore throat. However, all 
S pyogenes isolates cultured from samples submitted 
from the population of northwest London are collected 
and archived by the Imperial College Infection Biobank, 
allowing longitudinal study of strains causing both non­
invasive and invasive infections. Alongside the national 
reference laboratory, which systematically archives 
invasive S pyogenes isolates from across the country, the 
collection provides unique insight into the relationship 
between upper respiratory tract isolates and isolates from 
rare, but more severe and invasive, infections.
S pyogenes can be serotyped or genotyped on the basis of 
the M antigen, which is encoded by the emm gene. 
Changes in disease incidence are sometimes characterised 
by expan sion of specific emm genotypes.4 Using a 
combination of epidemiological and bacteriological 
approaches, we set out to identify the emm genotypes 
Research in context
Evidence before this study
In March to May of 2016, an unexpected elevation in 
notifications of invasive Streptococcus pyogenes infections in 
England was seen, coinciding with a national increase in 
notifications of seasonal scarlet fever (a paediatric exanthem also 
caused by S pyogenes). Since 2014, scarlet fever notifications in 
England have reached unexpectedly high levels, peaking between 
March and May each year, although notifications of invasive 
S pyogenes infections in 2014 were within expected limits, in 
contrast to 2016. We aimed to test the hypothesis that the link 
between scarlet fever and invasive infection patterns might be 
strain-related and, in the process, identified the emergence 
of a new M1T1 lineage. We searched PubMed for clinical and 
laboratory studies published before March 1, 2019, using the 
search terms “scarlet fever” and “upsurge” or “mortality”, as well 
as “emm1” or “M1T1” and “streptococcus”. We also searched 
using the terms “SpeA” or “scarlet fever toxin” or “erythrogenic 
toxin” and “streptococcus” and “regulation”. We identified 
studies describing recent and historical trends in scarlet fever 
incidence, studies that described trends in strain types causing 
invasive infections, and studies that linked SpeA to dominant 
strains. We also found studies of toxin expression that reported 
links with phage induction, growth phase regulation, 
transcriptional regulators, proteolysis, and host proteins as 
potential regulators.
Added value of this study
Our study provides a molecular explanation for the association 
between increased incidence of scarlet fever and increased 
incidence of invasive S pyogenes infections, by identifying an 
emergent lineage of M1T1 S pyogenes (M1UK) that expanded 
rapidly to become the largest single contributor to both 
non-invasive and invasive infections in 2016. The findings raise 
the possibility that historical associations between epidemic 
waves of scarlet fever and invasive infections might also have 
been linked to strain pathogenicity, in addition to general 
population susceptibility. Genomic analysis confirmed that the 
strains that cause scarlet fever are no different to those that cause 
streptococcal pharyngitis and rarer invasive infections. 
Increases in one disease could lead to increases in all, particularly 
if the lineage involved is highly pathogenic. The emergent lineage 
was characterised by a number of genetic changes that were 
predictive of increased production of SpeA, and this increased 
production was confirmed by laboratory testing. Although this 
might be just one of many changes in the new lineage, increased 
production of SpeA is predicted to enhance bacterial fitness, as 
suggested by the increasing dominance of the new lineage in 
comparison to older M1T1 strains in England. The work highlights 
that group A streptococcal lineages can differ in pathogenicity.
Implications of all the available evidence
Scarlet fever notifications in England in the period 2014–18 are 
the highest seen since 1960, and incidence in young children 
exceeds that reported in other countries. It is uncertain whether 
the increase in scarlet fever is a result of practice change or other 
population or environmental factors; the new lineage described is 
not implicated in the initial upsurge. However, there is a need to 
curtail this increasing trend. Interventions targeted at the 
population at risk have the potential to reduce the reservoir of 
S pyogenes that can seed more harmful invasive infections. 
Research to identify the most appropriate intervention is 
underway and practice guidelines for streptococcal pharyngitis 
might need to take strain variation and wider population effects 
into account. Increased S pyogenes disease activity could provide a 
platform for strain evolution and expansion, highlighting an 
unforeseen consequence of modern epidemics. The genetic 
changes in the emergent M1T1 clone require detailed laboratory 
investigation to understand the wider phenotypic changes that 
have occurred and the molecular basis for these, including 
transmissibility and response to treatment. It is not known 
whether the new lineage will recede in due course, as other 
lineages have done, or if it will remain dominant in the 
population, and surveillance is needed. Detection of new lineage 
representatives outside the UK underlines a need for global 
surveillance and increased vigilance if strains with increased 
fitness and altered phenotype are detected.
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responsible for S pyogenes infections during the 
2014–16 scarlet fever seasons regionally, then extended the 
study nationally, to identify bacterial determinants that 
might explain the observed increase in invasive disease 
due to S pyogenes in 2016.
Methods
S pyogenes notifications
Cases of suspected scarlet fever are notified by clinicians 
to Public Health England on the basis of symptoms and 
signs consistent with scarlet fever, with or without 
laboratory confirmation of S pyogenes infection. Scarlet 
fever has been notifiable since 1899 in England. Since 
2010, cases of invasive S pyogenes infections have also 
been notifiable to Public Health England, in accordance 
with statutory regulations.
S pyogenes isolates and emm genotyping
All non­invasive S pyogenes isolates submitted to the 
Diagnostic Laboratory at Imperial College Healthcare 
National Health Service Trust (London, UK) between 
Jan 1, 2009 and Dec 31, 2013, and between March 1 and 
May 31 each year during 2014–16 were cultured and stored 
frozen in glycerol (sampling rationale is detailed in the 
appendix p 29). This laboratory serves northwest London, 
a population of roughly 2 million people, representing 
approximately 3% of the population of England. Clinical 
data were linked to isolates and anonymised in accordance 
with research ethics approval (number 06/Q0406/20). 
Isolates were emm genotyped (appendix p 29). Laboratories 
from England and Wales are requested to submit sterile 
site and invasive S pyogenes isolates to the national 
reference laboratory, where emm genotyping is done on all 
submitted isolates. All isolates were cultured on Columbia 
blood agar (Oxoid, Basingstoke, UK) or in Todd­Hewitt 
broth (Oxoid) at 37°C with 5% CO2.
Genome sequencing
All non­invasive emm1 S pyogenes isolates collected from 
northwest London from 2009 to 2016 were subject to 
genome sequencing (appendix p 29), as were invasive 
emm1 isolates collected from England and Wales from 
March to May of 2013 and 2016. Comparative genomic 
analysis of invasive isolates was done with new (2013 and 
2016) and existing (2014–15)6 genome sequence data 
(appendix p 12–27). DNA from S pyogenes isolates was 
prepared, sequenced, analysed, and compared with 
published data from the UK (2007–12), North America, 
Nordic regions, and southeast Asia6–11 (appendix pp 28–29). 
All new genome sequence data generated in this 
study have been submitted to the European Nucleotide 
Archive) under the accession numbers listed in the 
appendix (pp 8, 12).
Quantification of speA production
Transcript expression of speA, encoding streptococcal 
pyrogenic exotoxin A (SpeA; also known as scarlet fever or 
erythrogenic toxin  A), was quantified by real­time PCR 
using a standard curve method. SpeA protein expression 
in 5 × concentrated overnight supernatants was assessed 
with western blotting, and compared with a recombinant 
SpeA standard (appendix pp 29, 30). For SpeA protein 
testing, one or two isolates per year (2009–15) per lineage 
(M1global vs M1UK) were randomly selected by lot, after 
excluding any strains with mutations in the two­component 
regulator covRS (also known as csrRS), which is known to 
repress a number of virulence factors, including SpeA.12
Statistical analysis
Datasets were compared with a two­tailed Mann Whitney 
U test for continuous data or a χ² test for categorical data, 
using GraphPad Prism 5.0 software. p values less than 
0·05 were considered to indicate statistical significance. 
To assess trends in invasive disease incidence, Poisson 
regression in Stata (version 15) was done using mid­year 
population denominators for England from the Office for 
National Statistics.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
The northwest London population had a year­on­year rise 
in scarlet fever notifications between 2014 and 2016 that 
was representative of the country as a whole when 
compared with national notification data (figure 1A). We 
also compared notifications of invasive S pyogenes 
infections in northwest London with national data 
(appendix p 2), which showed a marked increase in 
S pyogenes invasive disease in 2016 in northwest London 
during the scarlet fever season that also mirrored the 
national pattern of increased notifications in 2016.
emm genotypes of all S pyogenes upper respiratory tract 
isolates obtained in northwest London during the 
scarlet fever seasons spanning 2015 and 2016 were 
ascertained and compared with existing data from 2014.4 
emm1 upper respiratory tract strains increased in 
frequency year­on­year in the scarlet fever seasons, from 
five (5%) of 96 isolates in 2014, to 28 (19%) of 147 isolates 
in 2015 (p=0·0021 vs 2014 value), and 47 (33%) of 144 in 
2016 (p=0·0080 vs 2015 value); in 2016, emm1 became 
the single most frequent S pyogenes genotype causing 
upper respiratory tract infections (figure 1B). The 
increase in emm1 strains in 2016 contrasted with 
the previously reported associations of emm3 and 
emm4 strains with the initial upsurge in scarlet fever 
in 2014.4 Brief clinical details were supplied for 
243 of 387 upper respiratory tract isolates overall, 
among which 53 (22%) mentioned scarlet fever. Of 
these scarlet fever­associated isolates, those genotyped 
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as emm1 increased from zero (0%) of 17 in 2014, to 
four (24%) of 17 in 2015, and seven (37%) of 19 in 2016 
(p=0·0053 vs 2014 value).
To identify any genetic basis for the expansion of 
emm1 S pyogenes among upper respiratory tract isolates 
collected in London, the genomes of all non­invasive 
emm1 isolates available from northwest London from 
2009 to 2016 were sequenced (n=135). Single­nucleotide 
polymorphism (SNP)­based analysis of emm1 strains 
pointed to the emergence of a new emm1 lineage 
(designated M1UK), which could be differentiated from the 
contemporary emm1 population (M1global) by the presence 
of 27 core SNPs in regulatory and metabolic genes 
(figure 2, appendix p 7). The earliest member of the M1UK 
lineage was identified in 2010, and five intermediate 
isolates (with 13 or 23 of the unique SNPs) were detected 
between 2009 and 2012 (appendix p 3). Similarly to M1global, 
M1UK isolates were identified among all age groups, but 
included more cases of scarlet fever and evidence 
of recent transmissions than M1global (appendix p 3). 
From 2015 onwards, around two­thirds of non­invasive 
emm1 isolates from northwest London were within the 
new M1UK lineage (22 [71%] of 31 isolates in 2015, and 
30 [65%] of 46 in 2016). Recombination and pan­genome 
analyses provided no evidence for gain or loss of 
transferable elements when comparing M1global and M1UK 
strains. Lineage­specific acquisition of antimicrobial­
resistance genes was not detected; evidence of the mefA 
and msrD macrolide­resistance locus was found in just 
one M1UK isolate, while eight M1global isolates possessed 
antimicrobial­resistance genes (one isolate with the mefA 
and msrD locus, one with the tetracycline­resistance gene 
tetM, and six with the aminoglycoside­resistance gene 
aph3).
Scarlet fever is a toxin­mediated syndrome, historically 
associated with the expression of the phage­encoded 
Figure 1: 2016 surge in scarlet fever associated with expansion of emm1 upper respiratory tract isolates of 
Streptococcus pyogenes
(A) Monthly notifications of scarlet fever in northwest London (bars) in 2013–16 showing the surge in 
notifications between March and May, peaking in 2016. National scarlet fever notifications (dashed lines) 
are shown for comparison. (B) emm genotyping of all upper respiratory tract isolates of S pyogenes from 
northwest London between March and May each year during 2014–16. emm1 strains emerged as the 
dominant upper respiratory tract genotype by 2016.
Figure 2: Emergence of new emm1 lineage among non-invasive 
Streptococcus pyogenes isolates
Maximum likelihood phylogenetic tree constructed from core single-nucleotide 
polymorphisms (excluding prophage regions) of emm1 non-invasive isolates 
collected in northwest London in 2009–16 (n=135). Background shading in 
grey indicates the emergent lineage M1UK. 52 (85%) of 61 strains within the 
emergent lineage were isolated in either 2015 or 2016. The scale bar indicates 
the nucleotide substitutions per site. The black star indicates the reference strain 
MGAS5005. See appendix (p 3) for rooted tree with available metadata.
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erythrogenic toxin SpeA,13 the gene for which is possessed 
by all emm1 isolates studied in this investigation. 
Among the 27 M1UK lineage­defining SNPs, three non­
synonymous mutations were identified in the gene rofA 
encoding the standalone transcriptional regulator RofA,14 
which, alongside a homologue, nra, has been implicated as 
a repressor of SpeA production in some, but not all, 
streptococcal genotypes.15,16 Real­time PCR analysis of all 
sequenced non­invasive emm1 isolates from northwest 
London (n=135) indicated that the emergent lineage (M1UK) 
was associated with significantly increased transcription of 
speA compared with other contemporary emm1 isolates 
(M1global), suggesting that differential SpeA production was 
a feature of the M1UK lineage (figure 3A).
To ascertain whether this difference in transcription 
translated into a difference in SpeA protein expression, we 
compared ten M1UK (including one intermediate strain 
harbouring only 13 of the 27 lineage­defining SNPs) and 
ten M1global isolates and corroborated our finding that M1UK 
isolates had enhanced speA transcription (figure 3B). 
Quantitative western blot analysis of SpeA protein in 
bacterial overnight culture supernatant showed nine­times 
greater median SpeA production in the emergent M1UK 
lineage (190·2 ng/mL [IQR 168·9–200·4]) than in the 
M1global strains (20·9 ng/mL [0·0–27·3]; p<0·0001; 
figure 3C). The M1UK strain representing an intermediate 
genotype (13 of 27 SNPs, including the rofA SNPs) did not 
show enhanced SpeA protein secretion (figure 3C).
The sequence for speA in non­invasive M1UK and M1global 
isolates was identical to that of the reference strain 
MGAS5005. Integration sites for the phage carrying speA 
in sequenced non­invasive M1UK and M1global isolates were 
consistent with those in the reference strain, and mapped 
sequences from M1UK and M1global isolates were very similar 
(if not identical) to the reference strain phage 5005.1; no 
evidence of translocated superantigens or duplication of 
speA was found.
Although there was no rise in invasive disease 
notifications in 2014, the first year of elevated scarlet fever 
activity, a marked increase was seen nationally in the 
spring of 2016 compared with the same period (March to 
May) in the preceding 3 years (rate ratio 1·43 [95% CI 
1·31–1·56], p<0·001; appendix p 2). Although invasive 
disease case numbers in northwest London were modest 
when considered on a monthly basis by comparison 
with national data (appendix p 2), the seasonal increase in 
notifications matched that observed nationally. emm 
genotyping of all invasive disease isolates referred to 
the national laboratory showed significant absolute and 
relative year­on­year increases in emm1, from 183 (31%) of 
587 isolates between March and May 2015, to 267 (42%) of 
637 in the same period in 2016 (p<0·0001 vs 2015 values), 
peaking March 2016 (figure 4A).
To ascertain whether invasive S pyogenes infections 
might be affected by the emergent M1UK lineage, we 
compared the genome sequences of 552 invasive emm1 
isolates (appendix p 12–27) in England and Wales from 
March to May each year during 2013–16. Focusing first on 
London, where sequence data from non­invasive isolates 
were available for comparison, SNP­based phylogenetic 
analysis showed intermingling of the 31 sterile­site invasive 
and 135 non­invasive isolates; 16 (84%) of 19 invasive 
Figure 3: Expression of scarlet fever toxin SpeA in emergent M1UK isolates and other emm1 isolates
Phenotypic comparison of emergent M1UK isolates with M1global strains. (A) Quantification of absolute copy number of speA transcripts relative to house-keeping gene 
proS in all genome-sequenced non-invasive isolates from northwest London (n=135). Isolates were assigned to each lineage on the basis of SNPs (appendix pp 7–11). 
Quantification of speA transcript expression (B) and SpeA protein concentration in supernatant (C) from randomly selected M1UK and M1global strains lacking any 
mutations in covRS (n=10 per group). Median values are shown by horizontal lines in each graph. p values are from Mann-Whitney U tests. Grey squares denote 
strains that are intermediate members of the M1UK lineage. SpeA=streptococcal pyrogenic exotoxin type A. 
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strains obtained in 2015 and 2016 lay within the emergent 
M1UK lineage, compared with just five (42%) of 12 obtained 
between 2013 and 2014 (appendix p 4). Four (13%) of 
31 invasive isolates were identical to, or no more than 
two SNPs different from, non­invasive isolates in the 
community, consistent with recent transmission.
We then analysed the genome sequences of all 
552 emm1 sterile site isolates collected between 
March and May each year from 2013 to 2016, obtained 
nationally from across different geographical locations 
in England and Wales. 425 (77%) of 552 invasive 
emm1 strains were within the new lineage (figure 4B), 
which was present in the UK invasive isolate population 
as early as 2013. Like M1global strains, M1UK strains 
were phylogenetically distinct from the historical UK 
emm1 scarlet fever speA­positive isolate NCTC8198 and 
emm1 speC­positive SF370 (appendix p 5). Longitudinal 
analysis of all available 1240 UK emm1 sequences 
(appendix p 28)6–8 obtained from invasive and non­invasive 
disease cases showed a yearly increase in M1UK such that, 
by 2016, M1UK strains represented more than 80% of all 
available emm1 isolates in the UK, outnumbering M1global 
strains (figure 5A).
Phylogenetic comparison of UK emm1 sequences with 
available international sequences from North America, 
Nordic regions, UK, and southeast Asia (appendix p 28)9–11 
confirmed that M1UK strains were distinct from the globally 
disseminated pandemic emm1 strains (figure 5B). A small 
number of intermediate isolates (possessing at least 13 of 
the 27 lineage­defining SNPs, including three SNPs in 
rofA) were identified in the UK and in Nordic countries, 
including Denmark (n=16), Finland (n=2), and Sweden 
(n=4; figure 5b, appendix p 6).10 M1UK isolates that possessed 
all 27 SNPs were, however, unique to the UK, except single 
sequences isolated in the USA in 20159 and in Denmark in 
2012,10 underlining the potential of the new lineage to 
disseminate internationally (figure 5B, appendix p 6).
Discussion
The modern era of resurgent invasive S pyogenes 
infections was heralded by reports of virulent strains 
producing the scarlet fever toxin SpeA17 and subsequently 
dominated by the emm1 lineage.10 In this study, we showed 
that the originally polyclonal upsurge of scarlet fever in 
England has more recently been characterised by the 
emergence of a new emm1 S pyogenes lineage that 
produces significantly higher levels of SpeA than other 
contemporary emm1 strains. The new M1UK lineage showed 
an apparent fitness advantage within the population, 
manifest during the scarlet fever seasons of 2015 and 
2016. Phylogenetic analysis showed the emergent lineage 
Figure 4: Prevalence of emm1 strains among invasive Streptococcus pyogenes 
infections nationally during scarlet fever seasons and emergence of 
M1UK lineage over time
(A) emm genotypes of invasive S pyogenes isolates referred to national reference 
laboratory per month during 2014–16. Increases in total invasive disease cases 
were observed locally and nationally during March to May 2016 (appendix p 2). 
(B) Maximum likelihood phylogenetic tree constructed from core 
single-nucleotide polymorphisms (excluding prophage regions) of 
genome-sequenced invasive emm1 S pyogenes isolates in England and Wales 
(n=552) between March and May each year during 2013–16. Shading in grey 
indicates the emergent lineage M1UK. Clustering was not observed based on 
geographical origin, indicating emergence of the lineage on a national level. The 
black star indicates the reference strain MGAS5005. The scale bar represents the 
number of nucleotide substitutions per site.
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to be the dominant cause of invasive S pyogenes infections 
in England in 2016, and indicated that isolates from 
symptomatic throat infections and scarlet fever represent 
the major reservoir for invasive infections. The data 
support the hypothesis that transmission of virulent 
emm1 strains with enhanced ability to cause scarlet fever 
could underlie the contem poraneous rise in invasive 
S pyogenes disease.
An unprecedented year­on­year increase in scarlet fever 
notifications, the underlying basis for which remains 
unclear,3,4 has been seen in England since 2014. Among 
children aged 1–4 years, the incidence of scarlet fever in 
2018 reached 1488 per 100 000.18 The increase in scarlet 
fever activity has followed secular changes in factors 
such as household structure (including use of childcare) 
and health­care use,4 as well as health­care policies,19 
although causal links have not been established. 
One unforeseen consequence of medical practice change 
was that the capacity to investigate such an upsurge was 
undermined by a reduction in diagnostic testing at the 
national level. In northwest London, however, where 
strains are collected for epidemiological analysis, a 
significant increase in genotype emm4 pharyngitis strains 
was observed during the 2014 upsurge in scarlet fever, 
while emm3 was the main genotype associated with 
physician­reported scarlet fever.4 emm1 was infrequent in 
2014, contrasting with the increase we observed between 
2015 and 2016, when genotype emm1 S pyogenes became 
the dominant cause of upper respiratory tract infections 
regionally, and invasive disease notifications nationally.
Our genome sequence analysis revealed the emergence 
of a new emm1 lineage, separated from all other 
emm1 strains by 27 unique core SNPs, including three 
within a gene encoding a potential SpeA regulator, RofA. 
SpeA is usually the only phage­encoded superantigen in 
contemporary emm1 S pyogenes, and has been implicated 
in the re­emergence of severe invasive S pyogenes 
infections in the 1980s.10,17 Although the roles of any 
specific SNPs were not investigated in the current study, 
we hypothesise that increased SpeA production by M1UK 
strains might be an important contributor to the apparent 
fitness of the new lineage within the nasopharynx. As a 
phage­encoded superantigen, SpeA is hypothesised to 
trigger scarlet fever in susceptible children, and has been 
shown to permit nasopharyngeal infection in humanised 
models of murine streptococcal infection, plus 
potential induction of immunity when administered as a 
toxoid.20 SpeA can trigger B cell death and abrogate 
immunoglobulin secretion by the human tonsil, and 
Figure 5: Longitudinal (A) and geographical (B) comparison of M1UK lineage 
with pandemic emm1 strains of Streptococcus pyogenes
(A) Proportions of M1UK and M1global isolates among total sequenced invasive and 
non-invasive emm1 S pyogenes isolates (n=1240) annually in the UK between 
2007 and 2016. (B) M1UK lineage in a global context. Maximum likelihood 
phylogenetic tree constructed from core SNPs (excluding prophage regions) 
comparing all sequenced UK emm1 isolates with the global emm1 populations 
from North America, Nordic countries, and Asia (n=2800 isolates). Shading in 
grey indicates the emergent lineage M1UK; orange arc indicates intermediate 
isolates that lie outside M1UK but possess 13 or more of the 27 SNPs present in 
M1UK, including three SNPs in rofA. UK and international emm1 isolates arise 
throughout the tree, but isolates within the M1UK lineage are exclusively from the 
UK, except two single isolates from Denmark and the USA (arrows). The scale bar 
indicates the number of nucleotide substitutions per site. See appendix (p 6) for 
the unrooted tree. SNPs=single-nucleotide polymorphisms.
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might contribute to recurrent tonsillitis in children.21,22 
Thus, production of SpeA might augment the ability of 
S pyogenes to cause scarlet fever and paediatric pharyngitis. 
Whether population immunity to SpeA will lead to an 
eventual decline in the lineage will be of interest to 
monitor.
Griffiths type 1 S pyogenes strains23 (later designated 
serotype M1; genotype emm1) were the first to be 
classically associated with scarlet fever in the early 
20th century. Although the oldest emm1 scarlet fever 
reference strains dating from the 1920s possess and 
produce phage­encoded SpeA24, emm1 strains circulating 
later in the mid­20th century lacked phage­encoded 
SpeA.10 The epidemic success of M1T1 clonal emm1 strains 
of S pyogenes that subsequently emerged in the 
1980s is attributed to acquisition of a more active 
NADase–streptolysin O locus, as well as acquisition of 
phage­encoded speA2, an allele of speA, and the DNAse­
encoding gene sda.10 It is, therefore, surprising that these 
epidemic emm1 strains, forming the M1global lineage, 
apparently produce very little SpeA in vitro. The three 
SNPs identified in the rofA gene might contribute to the 
greater abundance of SpeA produced by the emergent 
M1UK lineage strains, but appear insufficient alone to 
account for this change. Gene regulation could be 
affected by a number of the additional SNPs implicated. 
A shift to enhanced SpeA expression in the M1UK lineage 
might represent just one component of a new phase in 
the evolution of emm1, although we have not yet explored 
other aspects of bacterial fitness.
Since the late 2000s, increased scarlet fever notifications 
have been reported in China,25 South Korea,26,27 and 
Hong Kong.28 The M1UK lineage is distinct from 
emm1 sequences identified in Asia, where different, non­
emm1 genotypes have been reported as upsurge­
associated, and incidence in very young children does 
not approach that reported in England.25 Although the 
acquisitions of novel prophages and antimicrobial 
resistance have been highlighted as selective pressures 
in China and Hong Kong,28 no evidence to suggest that 
these are factors in England, or that the emergence of a 
single lineage was a trigger for the original upsurge in 
England, has been reported.3
Sampling of the non­invasive reservoir of S pyogenes in 
our study was limited to a single region of England, and 
single seasons in 2014–16; thus, we cannot be certain 
about whether the non­invasive isolate emm genotype or 
M1UK proportions altered outside these periods, and the 
analysis might be skewed through inadvertent inclusion 
of isolates from outbreaks. The collection used in this 
study, however, is the only systematic longitudinal 
collection of non­invasive strains available, and spans 
2009–16. None of the samples included was identified as 
outbreak­associated, although clinical details were 
imperfect.
Groups of isolates differing by two SNPs or less were 
identified among non­invasive M1UK isolates, suggesting 
recent transmission, whereas no such groups were 
observed among the M1global non­invasive isolates, albeit 
these were from 2009–2014 when emm1 isolates were 
much less frequently identified. Whether the findings 
reflect inadvertent sampling of small outbreaks or greater 
outbreak potential cannot be addressed using these data.
Regardless of the drawbacks of regional sampling, 
the detection of a new lineage and increase in invasive 
emm1 infections prompted sequencing of invasive 
emm1 isolates referred to the national reference 
laboratory, which confirmed emergence of the same 
lineage at a national level, and excluded any artefact 
introduced by regional sampling. Our phylogenetic 
analysis of invasive isolates focused on the same season, 
in order to understand a rise in invasive disease, but 
published genome­sequenced invasive strains from 
the UK outside these months also showed emergence of 
the same lineage. Although the new lineage outcompeted 
the contemporary emm1 strains that were sequenced 
during the period studied, we do not know whether the 
lineage’s success will endure.
Genetic analyses were limited by the nature of high­
throughput short­read sequencing data, which do not 
provide fully assembled genome sequences for each strain 
and the phages therein; other lineage­specific differences 
might yet be identified using different approaches. Our 
study also did not address the mechanistic basis for fitness 
in the new lineage or the molecular basis for increased 
SpeA expression; links to specific SNPs are by association 
only, and detailed experimental work is underway to 
address such questions.
Scarlet fever is a visible and readily recognisable 
manifestation of S pyogenes infection that affects children 
aged 4–6 years.3,4 Importantly, however, the surges 
observed in scarlet fever are accompanied by seasonal 
increases in streptococcal sore throat and tonsillitis in 
the wider population, also predominantly among 
children.29 Although we cannot rule out the possibility 
that the precursors (ie, intermediates) or founders of 
the M1UK lineage were imported, we speculate that a 
generalised increase in S pyogenes activity in the wider 
population—which coincided with England’s scarlet 
fever upsurges—might have provided the conditions 
required for adaptation and expansion of emm1 S pyogenes. 
Whether the M1UK lineage will be suited to other 
environments is unknown; management of streptococcal 
sore throat differs greatly between countries,30 as do other 
important factors such as climate. We previously reported 
the emergence of a new emm89 lineage that had lost the 
capsule locus but gained an active NADase–streptolysin 
O locus, in addition to four other major recombination 
events.31 This emm89 lineage has now been identified 
across several continents.32 The identification of two 
members of the new M1UK lineage among isolates outside 
the UK underlines the potential of such lineages to 
spread globally. Compared with other genotypes, 
emm1 S pyogenes has a recognised, heightened association 
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with invasive infections.9 The expansion of such a lineage 
within the community reservoir of S pyogenes might be 
sufficient to explain England’s recent increase in invasive 
infection. Further research to assess the likely effects of 
M1UK on infection transmissibility, treatment response, 
disease burden, and severity is required, coupled with 
consideration of public health interventions to limit 
transmission where appropriate. Wider national and 
global surveillance will provide clearer understanding of 
the lineage’s geographical reach and longer­term fitness, 
and permit enhanced public health readiness where 
necessary.
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